Advertisement

Topics

Barclays hebt Ziel für Astrazeneca auf 6300 Pence - 'Overweight'

04:52 EDT 3 Jul 2017 | FinanzNachrichten

Die britische Investmentbank Barclays hat das Kursziel für Astrazeneca vor Zahlen für das zweite Quartal von 6000 auf 6300 Pence angehoben und die Einstufung auf "Overweight" belassen. Er habe sei...

Original Article: Barclays hebt Ziel für Astrazeneca auf 6300 Pence - 'Overweight'

NEXT ARTICLE

More From BioPortfolio on "Barclays hebt Ziel für Astrazeneca auf 6300 Pence - 'Overweight'"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...